Skip to main content

Table 1 Clinicopathological characteristics

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

 

No. of patients (70)

%

Age, median (range, year)

70 (44–85)

 

Gender

Male

48

69

Female

22

31

Histology

Adenocarcinoma

54

77

Squamous

15

22

NOS

1

1

Stage

IIIB

3

4

IV

67

96

ECOG PS

0

25

36

1

39

56

2

6

8

Smoking habits

Never smoker

9

13

Former smoker

35

50

Smoker

26

37

Prior lines of therapy

Median 2 (range 1–6)

 

1

28

40

2

20

29

3

13

19

≥ 4

9

12

CEA (ng/ml) baseline

Median (range)

6.6 (0.80–2615)

 

Normal (< 5)

30

43

Elevated (≥ 5)

40

57

CYFRA 21-1 (ng/ml) baseline

Median (range)

5.0 (0.2–126.4)

 

Normal (< 3.3)

25

36

Elevated (≥ 3.3)

45

64

NSE (ng/ml) baseline

Median (range)

7.5 (3.1–46.8)

 

Normal (< 3.3)

56

80

Elevated (≥ 3.3)

14

20

  1. NOS, not otherwise specified; ECOG, Eastern cooperative oncology group; PS, performance status; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin fragment 19; NSE, neuron-specific enolase